Pretreatment of human mesenchymal stem cells with HMG-CoA reductase inhibitor improved efficiency of cardiomyogenic transdifferentiation

点击翻译按钮获取中文摘要

In this study, our challenge was to improve the efficacy of mesenchymal stem cell (MSC)transplantation in vivo by pretreatment of MSCs with HMG-CoA reductase inhibitor. After cardiomyogenic induction in vitro, preteatment with HMG-CoA reductase inhibitor significantly increased the cardio- myogenic transdifferentiation ef ficiency (CTE), which was calculated by immunocytochemistry using anti-cardiac troponin- I antibody. CTE was reduced by pretreatment with HMG-CoA reductase inhibitor and wortmannin, inhibitor of Akt.